Sustained-release liposomal anesthetic compositions

• US 8,182,835 B2
• Filed: 04/01/2005
• Issued: 05/22/2012
• Est. Priority Date: 09/18/1997
• Status: Expired due to Fees

• Current Assignee: Pacira Pharmaceuticals, Inc. (Pacira Biosciences, Inc.)
• Original Assignee: Pacira Pharmaceuticals, Inc. (Pacira Biosciences, Inc.)
• Inventors: Kim, Sinil, Kim, Taehee, Murdande, Sharad
• Primary Examiner(s): KISHORE, GOLLAMUDI S
• Application Number:
  US11/097,756
• Publication Number:
  US 20060078606A1
• Time in Patent Office: 2,608 Days
• Field of Search: 424/450, 264/4.1, 264/4.3, 264/4.6
• US Class Current: 424/450
• CPC Class Codes: A61K 31/167 having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• CPC Class Codes: A61K 31/40 having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 47/02 Inorganic compounds
• CPC Class Codes: A61K 47/12 Carboxylic acids; Salts or anhydrides thereof
• CPC Class Codes: A61K 9/0002 Galenical forms characterised by the drug release technique; Application systems commanded by energy
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61K 9/1271 Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers liposome as conjugate A61K47/6911
• CPC Class Codes: A61K 9/1277 Processes for preparing; Proliposomes
• CPC Class Codes: A61P 23/02 Local anaesthetics

Abstract

The invention provides a method for obtaining local anesthetics encapsulated in liposomes, such as multivesicular liposomes, with high encapsulation efficiency and slow release in vivo. When the encapsulated anesthetic is administered as a single intracutaneous dose, the duration of anesthesia and half-life of the drug at the local injection site is increased as compared to injection of unencapsulated anesthetic. The maximum tolerated dose of the encapsulated anesthetic is also markedly increased in the liposomal formulation over injection of unencapsulated anesthetic. These results show that the liposomal formulation of local anesthetic is useful for sustained local infiltration and nerve block anesthesia.

Claims

1. A multivesicular liposome formulation comprising bupivacaine phosphate made by a process comprising:

a) preparing a first aqueous component comprising at least one acid in sufficient quantity to solubilize bupivacaine or a salt thereof, said acid being phosphoric acid;

b) preparing a lipid component comprising at least one organic solvent, at least one amphipathic lipid, and at least one neutral lipid lacking a hydrophilic head group;

c) mixing said first aqueous component and said lipid component to form a water-in-oil emulsion, wherein at least one component comprises bupivacaine or a salt thereof;

d) mixing said water-in-oil emulsion with a second aqueous component to form solvent spherules; and

e) removing the organic solvent from the solvent spherules to form multivesicular liposomes.

2. The multivesicular liposome formulation made by a process of claim 1, wherein said amphipathic lipid is dierucoylphosphatidyl choline.

3. The multivesicular liposome formulation made by a process of claim 1, wherein said amphipathic lipid is dipalmitoylphosphatidyl glycerol.

4. The multivesicular liposome formulation made by a process of claim 1, wherein said neutral lipid is tricaprylin.

5. A pharmaceutical composition comprising multivesicular liposomes encapsulating bupivacaine phosphate, said multivesicular liposome comprising

bupivacaine or a salt thereof;

phosphoric acid;

a lipid component comprising at least one amphipathic lipid and at least one neutral lipid lacking a hydrophilic head group; and

,

optionally, a cholesterol and/or a plant sterol wherein said multivesicular liposome encapsulating bupivacaine is made by a process comprising;

a) preparing a first aqueous component comprising phosphoric acid;

b) preparing a lipid component comprising at least one organic solvent, at least one amphipathic lipid, and at least one neutral lipid lacking a hydrophilic head group;

c) mixing said first aqueous component and said lipid component to form a water-in-oil emulsion, wherein at least one component comprises bupivacaine or a salt thereof;

d) mixing said water-in-oil emulsion with a second aqueous component to form solvent spherules; and

e) removing the organic solvent from the solvent spherules to provide multivesicular liposomes encapsulating bupivacaine phosphate.

6. The pharmaceutical composition made by a process of claim 5, wherein said at least one amphipathic lipid is selected from the group consisting of dierucoylphosphatidylcholine and dipalmitoylphosphatidylglyceral.

7. The pharmaceutical composition made by a process of claim 5, wherein said at least one amphipathic lipid comprises dierucoylphosphatidylcholine.

8. The pharmaceutical composition made by a process of claim 5, wherein said at least one amphipathic lipid comprises dipalmitoylphosphatidylglycerol.

9. The pharmaceutical composition made by a process of claim 5, wherein said at least one neutral lipid comprises tricaprylin.

10. The pharmaceutical composition made by a process of claim 5, wherein said at least one amphipathic lipid comprises dierucoylphosphatidylcholine and/or dipalmitoylphosphatidyl glycerol, and said at least one neutral lipid comprises tricaprylin.

11. The pharmaceutical composition made by a process of claim 5, wherein the amphipathic lipid is dierucoylphosphatidylcholine and dipalmitoylphosphatidyl glycerol;

and each neutral lipid is selected from the group consisting of triolein, tripalmitolein, trimyristolein, trilinolein, tributyrin, tricaproin, tricaprylin, and tricaprin.

12. The pharmaceutical composition made by a process of claim 11, wherein the neutral lipid is tricaprylin.

13. The pharmaceutical composition made by a process of claim 12, including cholesterol.

14. A method providing regional anesthesia to a subject in need thereof by administering in a single dose a multivesicular liposome comprising a therapeutically effective amount of bupivacaine phosphate, wherein the multivesicular liposome comprises bupivacaine phosphate;

a lipid component comprising at least one amphipathic lipid and at least one neutral lipid lacking a hydrophilic head group; and

, optionally, a cholesterol and/or a plant sterol.

15. The method of claim 14, wherein the single dose administration is intracutaneously, subcutaneously, or via nerve block.

16. The method of claim 15, wherein the nerve block is local or regional nerve block.

17. The method of claim 14, wherein the regional anesthesia has a duration of 12 hours or more.

18. A method of treating post-operative or post-trauma pain in a subject in need thereof comprising administering in a single dose a multivesicular liposome comprising a therapeutically effective amount of bupivacaine phosphate, wherein the multivesicular liposome comprises bupivacaine phosphate;

a lipid component comprising at least one amphipathic lipid and at least one neutral lipid lacking a hydrophilic head group; and

, optionally, a cholesterol and/or a plant sterol.

19. The method of claim 18, wherein the single dose administration of a multivesicular liposome comprising a therapeutically effective amount of bupivacaine phosphate provides pain relief of 12 hours or more.

20. The method of claim 18, wherein the single dose contains from at least 20 mg of bupivacaine present in the phosphate salt form.

21. The method of claim 18, wherein the single dose contains from about 20 mg to about 300 mg of bupivacaine present in the phosphate salt form.